As I said, I think Lympro data could start to push

As I said, I think Lympro data could start to push in that direction. However, I think good data and CLIA submission will get it there. By that time revenue will be very close at hand. JV partner is what will help with the uplist. Maybe orphan designation as well. There could be multiple orphan approvals. So, JV partner can likely initiate the uplist. Orphans before and after uplist to stabilize share price after uplist. Revenue from Lympro will also keep share price propped up. Don't forget there is TBI, CTE, and Nuropro to learn more about soon. Oh yeah, spin out. Point is....there are so many catalysts that it is hard to speculate. It's going north and quick.